![Glen Y. Sato](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Glen Y. Sato
Corporate Officer/Principal bei Cooley LLP
Aktive Positionen von Glen Y. Sato
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Cooley LLP
![]() Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2006 | - |
The State Bar of California
![]() The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Corporate Officer/Principal | 18.11.2010 | - |
Karriereverlauf von Glen Y. Sato
Ehemalige bekannte Positionen von Glen Y. Sato
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACUCELA INC | Direktor/Vorstandsmitglied | 20.01.2010 | 02.05.2015 |
Independent Dir/Board Member | 01.08.2009 | 02.05.2015 | |
California State Bar Association | Corporate Officer/Principal | - | 15.05.2014 |
PDL BIOPHARMA, INC. | Finanzdirektor/CFO | 01.09.2005 | 01.09.2005 |
EXELIXIS, INC. | Finanzdirektor/CFO | 01.11.1999 | - |
General Counsel | 01.11.1999 | - | |
ANACOR PHARMACEUTICALS INC | Unternehmenssekretär | 20.05.2011 | - |
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | 01.05.2003 | - |
Ausbildung von Glen Y. Sato
Wesleyan University | Undergraduate Degree |
University of California, Los Angeles | Graduate Degree |
Statistik
International
Vereinigte Staaten | 11 |
Operativ
Corporate Officer/Principal | 3 |
Director of Finance/CFO | 2 |
Director/Board Member | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
EXELIXIS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Cooley LLP
![]() Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Commercial Services |
Acucela, Inc.
![]() Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
The State Bar of California
![]() The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Commercial Services |
Anacor Pharmaceuticals LLC
![]() Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
PDL BioPharma, Inc.
![]() PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
California State Bar Association |
- Börse
- Insiders
- Glen Y. Sato
- Erfahrung